study evaluating absorption, distribution, metabolism and excretion (ADME) of Single dose [14C] AZD2423 in Volunteers - ADME

Study identifier:D2600C00008

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open Label, Single Dose, Phase I Study to Evaluate the Excretion of Radioactivity, the Metabolic Profile, Pharmacokinetics, Safety and Tolerability Following Single Oral Administration of [14C]AZD2423 to Healthy Male Volunteers

Medical condition

Neuroscience

Phase

Healthy volunteers

Yes

Study drug

AZD2423

Sex

Male

Actual Enrollment

Study type

Observational

Age

50 Years - 65 Years

Date

Study Start Date: 01 Nov 2010

Primary Completion Date: 01 Dec 2010

Study Completion Date: 01 Dec 2010

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

London, United Kingdom

Arms	Assigned Interventions
Experimental: 1 Single cohort of 6 subjects	Drug: AZD2423 AZD2423

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1280&filename=CSR-D2600C00008.pdf
Download
CSR-D2600C00008.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

Marianne Kasti

+44 (0) 207 910 7700

Marianne.kasti@quintiles.co.uk

Investigators

Principal Investigator

Biljana Lilja

Astrazeneca